UGMEDIUM SIGNALOPERATIONAL10-K

UG achieved 20% revenue growth but saw significant margin compression, with operating income declining 39% despite higher sales.

The company appears to be experiencing profitability challenges as it scales, with substantially higher costs eating into margins even as revenue grows meaningfully. The language changes indicate operational shifts including discontinued industrial products and anticipated manufacturing of new sexual wellness products, suggesting the company is repositioning its product mix but struggling with execution efficiency.

Comparing 2026-03-27 vs 2025-03-21View on EDGAR →
FINANCIAL ANALYSIS

UG delivered strong top-line growth with revenue increasing 20% to $13.0M, but this came at a steep cost as operating income fell 39% to $2.2M and operating cash flow dropped 43% to $2.0M, indicating significant margin compression. The company's cash position weakened by 33% to $1.3M while capital expenditures were dramatically reduced by 86%, suggesting either completed investments or cash preservation measures. Overall, the financial picture shows a company growing revenue but struggling with profitability and cash generation, raising questions about operational efficiency and the sustainability of current growth strategies.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-86.4%
$433K→$59K

Capex reduced 86.4% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Operating Cash Flow
Cash Flow
-43.3%
$3.5M→$2.0M

Operating cash flow fell 43.3% — earnings quality concerns; investigate working capital changes and non-cash items.

Operating Income
P&L
-38.5%
$3.6M→$2.2M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Net Income
P&L
-35.2%
$3.3M→$2.1M

Net income declined 35.2% — review whether driven by operations, interest costs, or non-recurring items.

Cash & Equivalents
Balance Sheet
-33.3%
$1.9M→$1.3M

Cash declined 33.3% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Revenue
P&L
+20.3%
$10.8M→$13.0M

Revenue growing 20.3% — solid top-line momentum, watch margins for quality of growth.

Current Liabilities
Balance Sheet
-12.8%
$1.9M→$1.7M

Current liabilities reduced — improved short-term financial position and working capital health.

Accounts Receivable
Balance Sheet
+11.1%
$1.4M→$1.6M

Receivables grew 11.1% — monitor days sales outstanding for collection efficiency.

LANGUAGE CHANGES
NEW — 2026-03-27
PRIOR — 2025-03-21
ADDED
Such Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after the Registrant s fiscal year ended December 31, 2025.
2 SPECIAL NOTE ABOUT FORWARD LOOKING STATEMENTS This Annual Report on Form 10-K for the year ended December 31, 2025 ( Annual Report ) contains both historical and forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which provides a safe harbor for forward-looking statements by the Registrant about its expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters.
( Company ) is a Delaware corporation that, through its Guardian Laboratories division, manufactures, markets and develops specialty cosmetic, personal care and sexual wellness ingredients and a line of healthcare products including pharmaceuticals and medical lubricants.
We conduct various research and development ( R D ) activities.
Our R D department primarily develops new and unique specialty cosmetic and sexual wellness ingredients.
+7 more — sign up free →
REMOVED
( Company ) is a Delaware corporation that, through its Guardian Laboratories division, manufactures, markets and develops specialty cosmetic ingredients, pharmaceutical products, medical lubricants and sexual wellness ingredients.
Prior to July 1, 2023, we manufactured and reported sales of a line of specialty industrial products; however, this product line was discontinued after the second quarter of 2023 due to low sales volume with no growth prospects.
In October 2023, we entered into a distribution agreement with Brenntag Specialties, a global market leader in chemicals and ingredients distribution, for the distribution of our new Natrajel line of sexual wellness ingredients in the United States, Canada, Mexico, Central America and South America.
Although there were no sales of these products during 2024, we anticipate that we will begin manufacturing and reporting sales of this new line of products in 2025.
Our research and development department primarily develops new and unique specialty cosmetic and sexual wellness ingredients.
+7 more — sign up free →
MORE OPERATIONAL SIGNALS
HOFTHIGHHOFT completed a major divestiture of its Pulaski and Samuel Lawrence furniture ...
2026-04-17
CTRNHIGHCTRN underwent a dramatic operational turnaround with a complete repositioning f...
2026-04-15
ORBSHIGHORBS has undergone a complete business transformation from packaging and e-comme...
2026-04-15
BRFHHIGHBRFH completed a transformative acquisition of Arps Dairy in October 2025, drama...
2026-04-15
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →